RALBP1 and melanoma: Targeting RLIP76 is also a quite unique strategy because to date, there are no other targeting modalities that show such a broad spectrum of activity (lung, colon, prostate, kidney, melanoma, neuroblastoma, and pancreas) in both cell cultures and animal models, with inherent cancer specificity [22]–[24], [34], [48].